Viral Vector Downstream Purification Patents: Leaders, Filing Trends and Open Claim Space
22.2% concentration at the top. The five leading assignees hold 1,617 of 7,297 records in scope, a smaller concentration than in many biologics sub-fields, leaving room for new entrants to stake claims. Volume rose to a peak of 699 records in 2021, then eased to 458 by 2024 — a 34% decline over that span. Earlier growth from 438 records in 2017 reflects a field that was still building out its process-patent base; the post-peak pullback is consistent with a maturing set of core downstream methods rather than an abandoned technology.
- 1REGENERON PHARMACEUTICALS INC6.1%
- 2THE TRUSTEES OF THE UNIV OF PENNSYLVANIA5.0%
- 3ABBVIE INC3.9%
- 4AMGEN INC3.9%
- 5GENENTECH INC3.2%
See the full viral vector downstream purification analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who holds the most patents in viral vector downstream purification?
The dataset ranks 100 assignees by record count, with the leading assignee holding 442 records and the fifth-placed assignee holding 236. The top five assignees combined account for 1,617 records, 22.2% of the 7,297 records in scope, which is a moderate concentration rather than a monopoly on the space. A long tail of filers with far fewer records each fills out the rest of the ranking, so freedom-to-operate work typically needs to look well past the leaders.
Is filing activity in viral vector purification still growing?
Filing volume rose from 438 records in 2017 to a peak of 699 in 2021, then declined to 458 by 2024, a 34% drop over that three-year span. 2024 is the most recent year that can be treated as a complete filing year; 2025 and 2026 figures will continue to rise as publications catch up, since publication typically lags filing by about 18 months. The honest read is a field that has passed its filing peak but still generates several hundred new records a year.
What patent classes dominate viral vector purification filings?
C07K (peptides and proteins) appears in 50.3% of the 7,297 records, C12N (microorganisms and genetic engineering) in 45.4%, and A61K (medicinal preparations) in 44.1%. Classes tied more directly to purification hardware are thinner: B01D (separation processes) sits at 10.8% and C12M (bioreactors and enzyme apparatus) at 4.2%. This tells you most claims are anchored to the biologic or its therapeutic use, with the process step claimed alongside it rather than standing alone.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Viral Vector Downstream Purification covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.